drug-eluting stent


Also found in: Dictionary, Thesaurus, Financial, Encyclopedia, Wikipedia.

drug-eluting stent

Abbreviation: DES
A stent coated with medications that it releases into surrounding intimal cells. It is designed to keep the lumen of an artery from closing both by holding the artery open and by retarding the growth of the vascular endothelium into the stent. See: bare metal stent
See also: stent
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents. An Observational Study of Drug-Eluting Versus Bare-Metal Stents.
Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: A network meta-analysis of 11 randomized, controlled trials.
Waksman, "Review: stent fracture in the drug-eluting stent era," Cardiovascular Revascularization Medicine, vol.
The study enrolled 8,583 patients at 11 sites in the US and Germany who underwent a percutaneous coronary intervention (PCI) with at least one drug-eluting stent between January 7, 2008, and September 16, 2010.
The drug-eluting stent releases drugs to the vessel wall to prevent inflammation and proliferation of cells, thus improving treatment outcomes.
In the global Horizons-AMI trial, 3,006 patients were randomized to receive either drug-eluting stents or bare-metal stents for the treatment of AMI, making it the largest randomized trial to study coronary stents in heart attack patients.
Drug-eluting stents can help reduce the occurrence of restenosis after balloon angioplasty and the placement of stents.
At a meeting in November 2007, the FDA's Circulatory System Devices Advisory Panel recommended approval of the drug-eluting stent (DES), under the condition that the manufacturer conduct certain postmarketing studies.
A cardiology database of 216 consecutive patients was used to identify patients with a paclitaxel (Taxus Express) drug-eluting stent inserted from December 1, 2002 to November 30, 2005.
Andrew Farb, a medical officer in CDRH's cardiology devices review branch, said a new focus for FDA in drug-eluting stent trials going forward will be to have sponsors more closely track actual prescription patterns for dual antiplatelet therapy and see if there is any relation to clinical events.